These Two Things Are Needed For Thecompanycompetitive Strengthslow C These two things are needed for the company. Competitive strengths include being low-cost producers and offering differentiated products. A company's competitive strategy can involve adopting a low-price strategy, differentiating through branding, or focusing on niche markets. For Amgen, a leading American multinational chemical and biopharmaceutical company, leveraging these strengths and strategies is crucial to maintaining its competitive advantage in the highly competitive biotechnology industry.
Paper For Above instruction Amgen Inc. stands as a prominent player in the biotechnology and pharmaceutical industry, renowned for its innovation and focus on developing novel therapies. To maintain and enhance its competitive position, Amgen must capitalize on its core competitive strengths—being a low-cost producer and offering differentiated, high-quality products. These strengths enable the company to withstand competitive pressures and meet diverse customer needs while optimizing profit margins. One of Amgen’s primary competitive strengths lies in its ability to operate efficiently as a low-cost producer. Cost leadership enables the company to price its products competitively, thus gaining a larger market share and improving profitability. Amgen’s scale, technological efficiencies, and supply chain management contribute to its cost advantages. Economies of scale allow Amgen to reduce production costs, while advanced manufacturing processes enable the company to maintain high-quality standards at lower costs. Cost leadership also provides a buffer against price wars, especially in markets where generic or biosimilar equivalents threaten traditional pharmaceutical sales (Kumar & Singh, 2019). Simultaneously, Amgen’s commitment to product differentiation is a vital competitive strength. The company invests heavily in research and development (R&D) to innovate and develop differentiated products that address unmet medical needs. Its portfolio includes biologics targeting various diseases such as cancer, rheumatoid arthritis, and osteoporosis (Chakraborty, 2021). Differentiation through innovative formulations and branded therapies fosters customer loyalty, enhances brand recognition, and insulates Amgen from generic competition initially. The company's focus on biologics and biosimilars, markets characterized by high barriers to entry, further underscores its capacity for product differentiation (Carter & Williams, 2020). To effectively utilize these strengths, Amgen employs a combination of competitive strategies aligned with market demands. A low-price strategy enables the company to penetrate price-sensitive markets and